Landfar Bio-medicine Co., Ltd (SHE:000504)
China · Delayed Price · Currency is CNY 9.41
+0.13 (1.40%)
May 13, 2026, 3:04 PM CST
Landfar Bio-medicine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Operating Revenue | 512.79 | 415.94 | 134.26 | 136.44 | 194.48 | 156.54 |
Other Revenue | - | - | 0.19 | 0.35 | 5.86 | 0.08 |
| 512.79 | 415.94 | 134.45 | 136.79 | 200.35 | 156.62 | |
Revenue Growth (YoY) | 291.66% | 209.37% | -1.71% | -31.72% | 27.92% | -10.79% |
Cost of Revenue | 411.17 | 324.14 | 44.77 | 44.85 | 72.98 | 46.21 |
Gross Profit | 101.62 | 91.8 | 89.68 | 91.95 | 127.36 | 110.4 |
Selling, General & Admin | 56.48 | 66.41 | 82.37 | 89.66 | 112.91 | 105.39 |
Research & Development | 7.03 | 7.66 | 9.69 | 12.57 | 9.99 | 8.54 |
Other Operating Expenses | -13.7 | -13.13 | 0.66 | 0.23 | -6.41 | 1.3 |
Operating Expenses | 49.82 | 60.94 | 105.02 | 128.54 | 140.27 | 132.34 |
Operating Income | 51.8 | 30.86 | -15.34 | -36.59 | -12.91 | -21.94 |
Interest Expense | - | - | -1.46 | -11.07 | -12.9 | -15.96 |
Interest & Investment Income | 6.79 | 7.87 | 5.72 | 3.27 | 1.78 | 2.46 |
Currency Exchange Gain (Loss) | - | - | 0 | 0 | 0 | 0 |
Other Non Operating Income (Expenses) | -18.85 | -16.31 | -10.41 | -7.78 | 3.35 | -1 |
EBT Excluding Unusual Items | 39.74 | 22.42 | -21.5 | -52.17 | -20.68 | -36.43 |
Impairment of Goodwill | - | - | - | -6.46 | - | -2.79 |
Gain (Loss) on Sale of Investments | -0 | -0.17 | -0.01 | 0.03 | -0.06 | -0.31 |
Gain (Loss) on Sale of Assets | 0.01 | 0 | 0.16 | 11.9 | 0.08 | 0.03 |
Asset Writedown | -2.54 | -2.54 | -0.47 | -0.46 | -0.9 | 0 |
Other Unusual Items | - | - | 0.97 | 2.44 | - | 9.28 |
Pretax Income | 37.2 | 19.72 | -20.85 | -44.71 | -21.56 | -30.23 |
Income Tax Expense | 1.55 | 1.67 | 3.07 | 2.07 | 7.9 | 2.87 |
Earnings From Continuing Operations | 35.65 | 18.05 | -23.93 | -46.78 | -29.46 | -33.1 |
Minority Interest in Earnings | 6.5 | 10.78 | 4.08 | 18.61 | 17 | 13.98 |
Net Income | 42.15 | 28.83 | -19.85 | -28.17 | -12.46 | -19.13 |
Net Income to Common | 42.15 | 28.83 | -19.85 | -28.17 | -12.46 | -19.13 |
Shares Outstanding (Basic) | 320 | 320 | 331 | 313 | 311 | 319 |
Shares Outstanding (Diluted) | 320 | 320 | 331 | 313 | 311 | 319 |
Shares Change (YoY) | -3.31% | -3.16% | 5.67% | 0.51% | -2.30% | 17.27% |
EPS (Basic) | 0.13 | 0.09 | -0.06 | -0.09 | -0.04 | -0.06 |
EPS (Diluted) | 0.13 | 0.09 | -0.06 | -0.09 | -0.04 | -0.06 |
Free Cash Flow | -213.3 | -120.85 | -13.47 | 30.36 | 149.44 | 75.14 |
Free Cash Flow Per Share | -0.67 | -0.38 | -0.04 | 0.10 | 0.48 | 0.24 |
Gross Margin | 19.82% | 22.07% | 66.70% | 67.22% | 63.57% | 70.49% |
Operating Margin | 10.10% | 7.42% | -11.41% | -26.75% | -6.44% | -14.01% |
Profit Margin | 8.22% | 6.93% | -14.76% | -20.59% | -6.22% | -12.21% |
Free Cash Flow Margin | -41.60% | -29.06% | -10.02% | 22.19% | 74.59% | 47.97% |
EBITDA | 56.9 | 35.45 | -12.81 | -33.54 | -9.98 | -18.41 |
EBITDA Margin | 11.10% | 8.52% | -9.53% | -24.52% | -4.98% | -11.76% |
D&A For EBITDA | 5.1 | 4.59 | 2.53 | 3.05 | 2.93 | 3.53 |
EBIT | 51.8 | 30.86 | -15.34 | -36.59 | -12.91 | -21.94 |
EBIT Margin | 10.10% | 7.42% | -11.41% | -26.75% | -6.44% | -14.01% |
Effective Tax Rate | 4.17% | 8.47% | - | - | - | - |
Revenue as Reported | - | - | 134.45 | 136.79 | 200.35 | 156.62 |
Advertising Expenses | - | - | 3.75 | 5.47 | 4.82 | 10.24 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.